52P - A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors

Date 05 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Selected poster presentations
Topics Cancer Immunology and Immunotherapy
Presenter Jose Medina
Citation Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047
Authors J. Medina1, M. Hinterberger2, M. Testori3, M. Geiger3, R. Giessel3, P. Chaplin3, H. Hochrein3, H. Lauterbach3
  • 1Immunology Research, Bavarian Nordic GmbH, 82152 - Martinsried/DE
  • 2Bavarian Nordic GmbH, 82152 - Martinsried/DE
  • 3Bavarian Nordic GmbH, Martinsried/DE

Abstract

Virus-based vaccines and appropriate costimulation enhance potent antigen-specific T cell immunity against cancer. In the present study we exploit both innate and adaptive immune responses triggered by a novel recombinant modified vaccinia virus Ankara (rMVA) encoding costimulatory CD40L against solid tumors in combination regimes to overcome tumor-induced resistance to immunotherapy.